Skin Diseases clinical trials at UCSD
1 research study open to eligible people
Showing trials for
Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
open to eligible people ages 6-17
The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age. The study is divided into 4 periods, a 5-week Screening period, a 36-week Double-Blind Treatment Period, an approximately 2-year Long-term Extension Period, and a 4-week Post-treatment Follow-up period.
San Diego, California and other locations
Our lead scientists for Skin Diseases research studies include Dawn Eichenfield.
Last updated: